



## Final Appraisal Recommendation

### Ferric carboxymaltose (Ferinject<sup>®</sup>▼)

Submission by:  
Vifor Pharma UK Limited

Advice No: 1011 – July 2011

#### Recommendation of AWMSG

Ferric carboxymaltose (Ferinject<sup>®</sup>▼) is recommended as an option for use within NHS Wales for the treatment of patients with iron deficiency when oral iron preparations are ineffective or cannot be used.

Ferric carboxymaltose (Ferinject<sup>®</sup>▼) should be restricted for use in non-haemodialysis patients only.

AWMSG is of the opinion that Ferric carboxymaltose (Ferinject<sup>®</sup>▼) is not suitable for shared care within NHS Wales for the above indication.

#### Additional notes:

In reaching this recommendation AWMSG took account of the [AWMSG Secretariat Assessment Report](#), the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, [clinical expert opinion](#), lay/patient/carer perspective and discussions at AWMSG.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: